Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 3, 2026

Silicon Motion Announces Results for the Fourth Quarter and Year Ended December 31, 2025

View original at globenewswire.com
“For the fourth quarter of 2025, net sales (GAAP) increased sequentially to $278.5 million from $242.0 million in the third quarter of 2025.”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • New products and opportunities across all business lines are expected to ramp in 2026, driving revenue acceleration and profitability growth

    80% confidence

  • Company experienced strong growth in automotive segment primarily driven by increased product diversification and new customer ramps

    80% confidence

  • New initiatives in enterprise and automotive are beginning to take hold and will represent significant growth drivers long-term for the company

    80% confidence

  • Momentum in increasing market share, growing customer and product portfolio, and expanding into new markets has never been stronger entering 2026

    80% confidence

  • Based on existing backlog for Q1 2026 and full-year, company anticipates a significantly stronger-than-seasonal start with sustained and steady growth throughout the year

    80% confidence

  • eMMC and UFS products increased sequentially during Q4 2025, primarily driven by market share gains

    80% confidence

  • Client SSD controller sales grew over 25% quarter-over-quarter in Q4 2025, primarily driven by industry-leading 8-channel and newly introduced 4-channel PCIe5 controllers

    80% confidence

  • Fourth quarter 2025 outperformance was driven by strength across all business lines as new products continued to ramp, with further market share gains in eMMC/UFS and client SSDs

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com